Sanofi
FDA grants fast track designation to chlamydia vaccine candidate
March 28, 2025Research and Development FDA, Infections and infestations, Sanofi, chlamydia, vaccination
The US Food and Drug Association (FDA) has granted fast track designation to Sanofi’s mRNA vaccine candidate for the prevention …
Results from Sanofi’s ALTUVIIIO XTEND-Kids phase 3 trial published in NEJM
July 22, 2024Research and Development Altuviiio, Haematology, Sanofi, haemophilia
Sanofi has announced that full results from the XTEND-Kids phase 3 study were published in The New England Journal of …
Sanofi shares results from phase 2 trial for frexalimab in MS treatment
July 1, 2024Research and Development MS, Neurology, Sanofi, multiple sclerosis
Sanofi has announced new phase 2 trial data for its CD40L monoclonal antibody, frexalimab, for the treatment of patients with …
Sanofi shares phase 3 trial results for Sarclisa in multiple myeloma treatment
June 5, 2024Research and Development Oncology, Sanofi, Sarclisa, clinical trial, multiple myeloma
Sanofi has announced data from the IMROZ phase 3 trial which assessed Sarclisa (isatuximab) in combination with standard-of-care bortezomib, lenalidomide …
Sanofi, Formation Bio and OpenAI enter AI collaboration
May 22, 2024Research and Development Formation Bio, OpenAI, Pharmacy, Sanofi, collaboration
Sanofi, Formation Bio and OpenAI have announced that they have entered into a collaboration with the aim of building AI-powered …
Fulcrum Therapeutics and Sanofi enter collaboration for facioscapulohumeral muscular dystrophy treatment
May 14, 2024Research and Development Musculo-skeletal disorder, Sanofi, collaboration, fulcrum therapeutics, muscular dystrophy
Fulcrum Therapeutics has announced that it has entered into a collaboration and license agreement with Sanofi for the development and …
Sanofi adds €1bn funding for biomanufacturing projects in France
May 13, 2024Business Services Biomanufacturing, Pharmacy, Sanofi, funding, investment
Sanofi has announced that it has made a new investment of at least €1bn for the creation of new bioproduction …
Sanofi and Novavex sign exclusive $1.2bn licensing agreement to co-commercialise COVID-19 vaccine and develop flu-COVID-19 vaccines
May 10, 2024Sales and Marketing COVID-19, COVID-19 vaccine, Immunology, Novatex, Sanofi, flu-COVID-19 vaccine, licensing agreement
French pharma and healthcare company Sanofi and US biotech Novavex, have entered into a co-exclusive licensing agreement for a number …
Sanofi shares results for phase 3 LUNA 3 trial in immune thrombocytopenia
April 23, 2024Research and Development Cardiology, Sanofi, clinical trial, thrombocytopenia
Sanofi has announced positive results from its phase 3 LUNA 3 study, which assessed rilzabrutinib 400mg twice daily oral treatment …
Sanofi shares phase 2b results for dermatitis treatment
March 12, 2024Research and Development Dermatology, Sanofi, amlitelimab, atopic dermatitis, clinical trial, dermatitis
Sanofi has shared positive results from part 2 of the investigational phase 2b STREAM-AD study of amlitelimab for adult patients …
Sanofi to acquire Inhibrx for approximately $1.7bn
January 23, 2024Business Services Inhibrx, Rare Diseases, Sanofi, acquisition
Sanofi and Inhibrx, Inc have announced that they have entered into a definitive agreement for Sanofi to acquire Inhibrx following …
AstraZeneca and Sanofi’s Beyfortus approved in China
January 2, 2024Research and Development AstraZeneca, Beyfortus, China, Immunology, Sanofi
AstraZeneca and Sanofi have announced that Beyfortus (nirsevimab) has been approved in China for the prevention of respiratory syncytial virus …
Sanofi and Regeneron share results from phase 3 trial for Dupixent as COPD treatment
November 27, 2023Medical Communications COPD, Cardiology, Dupixent, Sanofi, clinical trial
Sanofi and Regeneron have announced results from the second investigational phase 3 NOTUS trial for Dupixent as a treatment for …
Sanofi shares new data for long-term efficacy of Nexviazyme for Pompe disease treatment
October 6, 2023Research and Development Nexviazyme, Pharmacy, Pompe disease, Sanofi
Sanofi has shared new data for the long-term efficacy of Nexviazyme (avalglucosidease alfa) for the treatment of Pompe disease at …
Janssen and Sanofi enter agreement for potential vaccine programme
October 5, 2023Business Services Immunology, Janssen, Sanofi, e coli, vaccines
Janssen Pharmaceuticals, a Johnson & Johnson company, has announced a development and commercialisation agreement with Sanofi for Janssen’s extraintestinal pathogenic …
Latest content
Five Facts about cardiovascular disease
